PCOV: Presynaptic Imaging in Major Depressive Episodes After COVID-19
Study Details
Study Description
Brief Summary
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Participants will undergo two positron emission tomography (PET) scans, one [11C]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one [18F]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan.
The main question[s] it aims to answer are:
-
The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP.
-
The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| COVID-DNP Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE). |
Other: [11C]DTBZ PET scan
One [11C]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
Other: [18F]SDM8 PET scan
One [18F]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
Other: MRI scan
One MRI scan
|
| Healthy Control Participants in good physical health, age- and sex-matched to Group 1 and 2 participants. |
Other: [11C]DTBZ PET scan
One [11C]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
Other: [18F]SDM8 PET scan
One [18F]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
Other: MRI scan
One MRI scan
|
Outcome Measures
Primary Outcome Measures
- Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND) [within 3 to 4 weeks after initiation of screening]
The investigators will determine if VMAT2 BPND is changed in ventral striatum and dorsal putamen in COVID-DNP.
- Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT) [within 3 to 4 weeks after initiation of screening]
The investigators will determine if SV2A VT is changed in ventral striatum and dorsal putamen in COVID-DNP
Eligibility Criteria
Criteria
Inclusion Criteria:
-
New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined.
-
Age 18 to 75.
-
Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
Exclusion Criteria:
-
Use of antidepressants in the previous month (6 weeks for fluoxetine).
-
Use of stimulant medication affecting dopamine release in the previous month
-
Use of antipsychotics in the previous month
-
History of neurological disease (except migraine, and PASC) based on self-report
-
Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report
-
Presence of cigarette smoking in the past two months, based on self-report
-
Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
-
Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
-
Positive urine drug or cotinine screen at any timepoint during the study
-
History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
-
Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan)
-
Breastfeeding (for females)
-
Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report
-
Claustrophobia, based on self-report
-
Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns)
-
Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report
-
Severe allergic reaction to alcohol
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre for Addiction and Mental Health | Toronto | Ontario | Canada |
Sponsors and Collaborators
- Centre for Addiction and Mental Health
Investigators
- Principal Investigator: Jeffrey Meyer, M.D., PhD, Centre for Addiction and Mental Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- REB#201/2022